Fresenius Kabi has warned that the potential of a US Food and Drug Administration warning letter against its large-scale sterile injectables plant in Melrose Park near Chicago “cannot be excluded,” while stressing that it is by no means a “given that we are going to receive one.”
Last year, an FDA inspection at Melrose Park revealed multiple Form 483 deficiencies, including a failure to properly deal with...





